Wellcome Sanger Institute

Cancer Dependency Map Analytics

Cancer, Ageing and Somatic Mutation

We design algorithms and computational tools for the analysis of large-scale cancer pharmacogenomics and functional genomics datasets (from chemical and genome-editing screens) to the aim of identifiying new oncology therapeutic targets and markers of gene-essentiality/drug-response.

In partnership with Open Targets, we provide computational support and analytic solutions to the international Cancer Dependency Map consortium, and to other projects engaged in the analysis of data from large-scale chemo/genetic screens.

Our people

Group lead

Dr Francesco Iorio

Principal Staff Scientist

Francesco is responsible for the design of analytical methods and software, and the management of day-by-day operations to deliver scientific milestones toward the definition of a global Cancer Dependency Map: an atlas of genetic dependencies and vulnerabilities, at an individual cancer cell resolution, which could be exploited for the development of cancer targeted and personalized therapies.

Core team

Dr Hanna Najgebauer

Open Targets Postdoctoral Fellow

Dr Clare Pacini

Principal Bioinformatician

Previous team members

Dr Ichcha Manipur

Visiting Scientist

Valeria Mirici Cappa

Visiting Scientist

Alessandro Vinceti

Visiting Scientist

Associated research

Collaborations

Collaboration

Cancer Dependency Map

The Cancer Dependency Map integrates the work of multiple experimental and computational research project at the Sanger Institute with the ...

Tools & software

Tool

ADaM

ADaM (Adaptive Daisy Model): an R package for discriminating between core fitness and context-specific fitness genes in large-scale gene essentiality ...

Tool

CRISPRcleanR

An R package for unsupervised identification and correction of gene independent cell responses to CRISPR-cas9 targeting

Related groups

Science group

Adams Group

Experimental Cancer Genetics

We are a team of cancer biologists, geneticists and computational biologists interested in understanding how cancers develop and the ways of ...

Science group

Garnett Group

Translational Cancer Genomics

The Translational Cancer Genomics team investigate how genetic alterations in cancer contribute to disease and impact on response to therapy.

Science group

Parts Group

Understanding human DNA function by engineering

Our goal is to mechanistically understand impact of mutations in human DNA. To do so, we engineer DNA variation in cells, ...

Science group

Yusa Group

Stem Cell Genetics

The Yusa laboratory focuses on the development of genome engineering technologies that allow us to perform unbiased genome-wide genetic screens ...

Wellcome Sanger Institute

Programmes and Facilities

Programme

Cancer, Ageing and Somatic Mutation

The Cancer, Ageing and Somatic Mutation Programme pioneers data aggregation and informatics innovation, develops high-throughput cellular models of cancer for genome-wide ...

Partners

We work with the following groups

External

Open Targets

Open Targets is a pioneering public-private partnership between Biogen, Celgene, EMBL-EBI, GlaxoSmithKline (GSK), Takeda, and the Wellcome Sanger Institute and is located on the Wellcome Genome Campus. Open Targets brings together expertise from six complementary institutions to systematically identify and prioritise targets from which safe and effective medicines can be developed, to help others find good targets, and to get those targets adopted into drug discovery pipelines.Current focuses are oncology, immunology and neurodegeneration through an R&D framework that can be applied to all aspects of human disease.